Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)
- DOI
- 10.1007/s13555-026-01810-1
- Published
- 2026-06-19
- Container
- Dermatology and Therapy
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s13555-026-01810-1,
title = {Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)},
author = {Emma Guttman-Yassky and Alan D. Irvine and Melinda Gooderham and Stephan Weidinger and Lynda Spelman and Jonathan I. Silverberg and Heidi Crane and Hany ElMaraghy and Louise DeLuca-Carter and Maria Lucia Buziqui Piruzeli and Georgia Martimianaki and Evangeline Pierce and Helena Agell and Diamant Thaçi},
year = {2026},
journal = {Dermatology and Therapy},
doi = {10.1007/s13555-026-01810-1},
url = {https://doi.org/10.1007/s13555-026-01810-1}
}RIS
TY - JOUR TI - Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin) AU - Emma Guttman-Yassky AU - Alan D. Irvine AU - Melinda Gooderham AU - Stephan Weidinger AU - Lynda Spelman AU - Jonathan I. Silverberg AU - Heidi Crane AU - Hany ElMaraghy AU - Louise DeLuca-Carter AU - Maria Lucia Buziqui Piruzeli AU - Georgia Martimianaki AU - Evangeline Pierce AU - Helena Agell AU - Diamant Thaçi PY - 2026 JO - Dermatology and Therapy DO - 10.1007/s13555-026-01810-1 UR - https://doi.org/10.1007/s13555-026-01810-1 ER -
APA
Guttman-Yassky, E., Irvine, A. D., Gooderham, M., Weidinger, S., Spelman, L., Silverberg, J. I., Crane, H., ElMaraghy, H., DeLuca-Carter, L., Piruzeli, M. L. B., Martimianaki, G., Pierce, E., Agell, H., & Thaçi, D. (2026). Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin). Dermatology and Therapy. https://doi.org/10.1007/s13555-026-01810-1
Source records
- crossref · retrieved 2026-09-25T16:20:10.313Z